PARK7 and breast carcinoma: In breast cancer, low PARK7 expression was correlated with pathological complete response in 79.6% of cases following neoadjuvant therapy (Kawate et al., 2013), and loss of PARK7 function is associated with increased sensitivity to doxorubicin in breast cancer cells (Zhang et al., 2015).